Investigational OCTA Devices Show Promise in Diabetic Disease Assessment - Takeaways - MDSpire

Investigational OCTA Devices Show Promise in Diabetic Disease Assessment

At Retina World Congress, Patricio G. Schlottmann, MD, discussed investigational widefield OCTA platforms made by Chinese company TowardPi Medical.

  • By

  • Patricio G. Schlottmann, MD

  • Patricio G. Schlottmann, MD

  • May 14, 2026

  • 2 min

Share

  • 1

    Investigational OCTA devices show promise in detecting peripheral diabetic retinal disease.

  • 2

    Ultrawidefield OCTA can evaluate patients with diabetic retinopathy and macular edema.

  • 3

    These OCTA devices are not yet licensed in the U.S. but are used as investigational tools.

  • 4

    OCTA provides a non-invasive method for assessing disease progression without pupil dilation.

  • 5

    The technology captures 24-mm images in one go, aiding in the management of diabetic eye disease.

Original Source(s)

Investigational OCTA Devices Show Promise in Diabetic Disease Assessment

  • by Patricio G. Schlottmann, MD, Patricio G. Schlottmann, MD

  • May 14, 2026

Related Content

Diabetic retinopathy and the risk of all-cause dementia, Alzheimer’s disease, and vascular dementia: a systematic review and meta-analysis

Retinal Age as Disease Biomarker

Fundus-based AI screening can indicate “retinal age” of patients, as well as flag systemic disease risks, says new study

  • May 27, 2026

  • 3 min
Retinal Age Model Tied to Disease Risk

Fundus-based tool estimates biologic aging but shows modest gains over prior models